Cargando…
Late presentation of sorafenib-associated rash: a case report
INTRODUCTION: Sorafenib, an oral multitargeted tyrosine kinase inhibitor, is licensed for the treatment of hepatocellular carcinoma. Rash is one of the most common side effects of its use, generally appearing within days to a few weeks of commencing treatment. We report the first case of rash appear...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2974748/ https://www.ncbi.nlm.nih.gov/pubmed/20973944 http://dx.doi.org/10.1186/1752-1947-4-338 |